12/05/2026
Good morning from Berlin, where the final IMMUcan General Assembly starts today.
Over the past years, IMMUcan has grown into one of the largest efforts of its kind in Europe to profile the tumour microenvironment across cancer types. It feels like the right moment to look at what this project has actually built: patient cohorts across major cancer types, molecular and cellular profiling, spatial transcriptomics, proteomics, plasma profiling, imaging data, and analyses now moving into publications and reusable resources.
The project brought together clinicians, researchers, data scientists, hospitals, academic centres, industry partners, and patient organisations around one shared question: how can we better understand the tumour microenvironment so future cancer treatment becomes more precise?
Over the next two days, we’ll go through the science, the datasets, the publications, the lessons learned, and the work still needed to make sure the results continue to be useful beyond the project.
There’s always something slightly reflective about a final meeting. You start to see the project not just as a series of results, but as something that took time, coordination, and a lot of collective effort to come together.
